Article
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Clinical genitourinary cancer - 1 Mar 2026
Park Joseph J, Howard Lauren E, Fragkogianni Stamatina, George Daniel J, Armstrong Andrew J
Abstract excerpt
INTRODUCTION: Inactivating missense mutations in the SPOP gene increase the transcriptional activity of the androgen receptor and sensitivity to hormonal therapies in patients with hormone sensitive prostate cancer (HSPC). However, the relationship of SPOP alterations with differential outcomes by race, particularly in patients with castration-resistant prostate cancer (CRPC), remains unclear. PATIENTS AND...
Topics
Join the communities discussing this publication.
